Short Interest in Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Drops By 19.2%

Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) was the target of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 185,700 shares, a decrease of 19.2% from the January 15th total of 229,900 shares. Based on an average trading volume of 414,100 shares, the short-interest ratio is currently 0.4 days.

Shionogi & Co., Ltd. Trading Up 2.4 %

Shares of OTCMKTS:SGIOY traded up $0.17 during trading on Wednesday, reaching $7.21. The stock had a trading volume of 86,526 shares, compared to its average volume of 190,160. Shionogi & Co., Ltd. has a 52 week low of $6.22 and a 52 week high of $9.11. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.01 and a current ratio of 7.64. The firm's fifty day moving average is $7.08 and its 200 day moving average is $8.22. The stock has a market cap of $12.27 billion, a price-to-earnings ratio of 12.03, a P/E/G ratio of 2.31 and a beta of 0.23.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) last issued its quarterly earnings results on Friday, January 31st. The company reported $0.16 earnings per share for the quarter. Shionogi & Co., Ltd. had a return on equity of 12.02% and a net margin of 35.53%. As a group, equities analysts forecast that Shionogi & Co., Ltd. will post 0.66 EPS for the current fiscal year.

Shionogi & Co., Ltd. Company Profile

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.